Reduced methamphetamine use, relief of withdrawal, improved cognition and better daily functioning are related treatment goals, but they are not the same endpoint. A 2025 scientific opinion by McKetin and colleagues argues that pharmacotherapy research should give more attention to recovery after cessation, alongside efforts to reduce ongoing use.
A research argument, not a new treatment trial
The paper is classified as Current Opinion. It reviews clinical and preclinical findings to propose a direction for research; it does not randomize a new patient cohort, present a new pooled effect estimate or establish a treatment protocol. Its descriptions of medication availability and trial progress belong to its 2025 publication context.
For its broad discussion, the paper groups illicit methamphetamine and amphetamine under the term methamphetamine. That convention should not be carried into interpretation of a laboratory result: methamphetamine and amphetamine remain distinct analytes, and a study’s stated exposure definition matters.
Maintenance and recovery pose different questions
Much of the reviewed pharmacotherapy work tested ongoing medication while people continued using methamphetamine. The authors compare this maintenance approach with treatments aimed at initiating abstinence, managing withdrawal or addressing persistent functional problems afterward.
A medication could affect one stage without affecting another. A reduction in craving need not produce fewer drug-positive specimens. Improved attention need not demonstrate abstinence. Conversely, fewer reported use days do not independently establish restored cognition or employment. A trial must measure the outcome being claimed.
Why short withdrawal trials leave a gap
The opinion describes withdrawal trials lasting five to 28 days, most only one to two weeks. It contrasts those intervals with biological and functional changes that may persist longer. This mismatch motivates longer follow-up; it does not establish that every person has the same syndrome or requires the same intervention.
The paper distinguishes immediate rewarding effects from learned cue-related craving and from longer-lasting changes involving monoamine function, neuroplasticity, inflammation and oxidative stress. Human imaging, postmortem observations, animal experiments and molecular hypotheses contribute different kinds of support. A pathway implicated in an animal model is not yet a proven human therapeutic target.
A useful example of keeping the endpoint intact
The opinion discusses a lisdexamfetamine trial’s modest primary endpoint estimate. The original trial also reported different secondary results. Our analysis of the primary and secondary methamphetamine-use endpoints addresses that specific evidence. The opinion’s summary should not replace the original trial’s denominator, timing, confidence interval or retention account.
This separation applies to proposed recovery therapies as well. A feasibility finding from an open-label pilot is not a placebo-controlled efficacy result. A mechanistic rationale is not evidence that an available drug improves quality of life. Positive results on one cognitive task are not evidence of global rehabilitation.
What would a recovery-focused trial need to establish?
The authors’ agenda suggests testing more than a single use measure. A study could prespecify withdrawal severity, retention, repeated cognitive assessments, functioning and relapse over relevant intervals. The resulting outcomes would still require independent interpretation, suitable controls, attention to missing data and protection against overreading multiple comparisons.
Repeated cognitive testing especially needs to distinguish improvement beyond practice from familiarity with the task. Biological change should be paired with functional measurement rather than labeled recovery by itself. Treatment engagement is valuable, but remaining in a study does not establish cessation of use.
What the opinion supports today as a scientific source
Its contribution is a clear research distinction: ongoing-use reduction and post-use functional recovery should both be investigated. It does not demonstrate that its proposed approaches work, that maintenance treatment has no value, or that any one medication should be prescribed on this reasoning alone. The evidence supports further testing of defined goals in defined populations.
Source
McKetin R, Kim JH, Turner A, Berk M. Methamphetamine pharmacotherapy: a need to re-focus on the complex neurobiological changes that occur both during and after methamphetamine use disorder. CNS Drugs. 2025;39:1061–1070. doi:10.1007/s40263-025-01214-3. Scientific opinion and narrative synthesis, reflecting the evidence discussed in 2025.
Leave a Reply